INTRODUCTION
Incisional glaucoma surgery is generally indicated when medical therapy and laser treatments fail to control intraocular pressure (IOP) adequately. Trabeculectomy remains the most commonly performed incisional glaucoma surgery worldwide [1] . However, recent surveys of the American Glaucoma
Society have shown an increase in the proportion of practitioners using tube shunts and a decrease in the popularity of trabeculectomy [2] . Medicare data has also demonstrated an increase in the number of tube shunts with a decline in trabeculectomies 
METHODS
The Institutional Review Board of the Statistical analyses were performed using the two-sided Student t-test for continuous variables. Snellen VA measurements were converted to logarithm of the minimal angle of resolution (logMAR) equivalents for the purpose of the data analysis. A p value of 0.05 or less was considered statistically significant in our analyses. Failed eyes were excluded from further analyses of IOP, VA, or glaucoma medications beyond the time-point of failure.
Compliance with Ethics Guidelines
The Institutional Review Board of the University of Illinois at Chicago Human Subject Research Committee approved this study. Informed consent was obtained from all patients for being included in the study.
RESULTS
Baseline characteristics of study patients are presented in Table 1 . A total of 37 patients met the eligibility criteria for the study. The majority of patients were male (62%) and most patients were African American (51%). The most common diagnosis was primary open-angle glaucoma (POAG, 73%).
Baseline and follow-up IOP measurements are shown in Table 2 and Fig. 1 . The number of patients who were censored at 3 months, 6 months, and 1 year was 2 at each time point.
Additional reduction in the number of patients at follow-up time points was the result of missed visits. IOP was consistently and statistically significantly lower at each follow-up time point compared to IOP at baseline.
The number of glaucoma medications at baseline and follow-up is reported in Table 2 and Data is presented as mean ± standard deviation IOP intraocular pressure Trabeculectomy has shown to be effective at reducing IOP and reducing the risk of progressive glaucomatous visual field loss [8, 9] . Antimetabolites such as MMC or 5-FU augment that IOP reduction and can enhance the success rate of trabeculectomy surgery; [10, 11] indeed, antimetabolite therapy is routinely combined with trabeculectomy among most glaucoma practitioners [12] .
However, adjunctive antimetabolite therapy is associated with significant complications, including bleb leaks, hypotony, and cataract [10] . Although there was less need for supplemental medical therapy after trabeculectomy at 1 year, vision loss occurred at a similar rate after both procedures [18] . At 5 years, the rates of late postoperative complications and reoperation for complications were similar. Overall rate of complications was significantly higher in the trabeculectomy group compared with the tube group: in particular, bleb leaks and dysethesia occurred with significantly greater frequency in the trabeculectomy group. In contrast, no postoperative complications were significantly more common in the tube group [16] . While a prospective study is underway comparing primary tube vs. trabeculectomy, the study suggests a favorable role in expanding the role of BGI.
Recently, outcomes were reported comparing the safety and efficacy of Baerveldt glaucoma implant surgery and trabeculectomy with MMC in patients who had not undergone prior incisional surgery [4] . At 6 months of follow-up, Baerveldt glaucoma implant surgery reduction, a result similar to earlier reports in the literature [4, [19] [20] [21] . Those IOP reductions were stable at 5 years in both groups, suggesting that the IOP at 6 months may be a good predictor of long-term IOP reduction. In the current study examining the efficacy of BGI as a primary glaucoma surgery, IOP was reduced from baseline by 49.5% at 6 months and 55.6% at 1 year. As in the study by Panarelli et al. [4] , IOP was reduced by 6 months and that reduction was stable at 1 year. These results are similar to those seen at similar postoperative time points in the tube group of the TVT study, where IOP was reduced from baseline by 50.1%
at 1 year following surgery in patients with prior incisional ocular surgery [16] . Patients in the current study required significantly fewer glaucoma medications at all time points following surgery. The mean number of glaucoma medications was 2.6 ± 1.2 at 6 months and 2.7 ± 1.7 at 1 year, somewhat higher than the mean number (1.8 ± 1.5 and 1.9 ± 1.5, respectively) reported in the Baerveldt group of the study by Panarelli et al. [4] , as well as that of the tube group of TVT at 1.3 ± 1.3 (at 1 year) [16] . Possibly medication non-adherence, a well-known challenge in glaucoma management [22, 23] , may have accounted for this difference.
There were a total of five postoperative complications in this study, including anterior chamber shallowing, hyphema, chronic iritis, persistent choroidal effusion, and rhegmatogenous retinal detachment. The overall rate of postoperative complications was 15%, similar to that seen in a recent study of patients undergoing primary BGI [4] . While that study included persistent corneal edema, bleb leak, and persistent diplopia as postoperative complications in the BGI group, in this study there were no patients with those complications. Although variability among practitioners may account for this difference, the current study was also not adequately powered to detect relatively rare complications of BGI surgery [15, 24] . Interestingly, in both the current study and that by Panarelli et al. [4] ., the overall complication rates (15% and 20%, respectively) were lower than the 34% rate observed in the tube group of the TVT study [25] .
Prior studies have indicated that postoperative visual acuity significantly decreased following BGI [4, 25] . In patients with no prior incisional ocular surgery, Snellen visual acuity decreased by more than two lines in 33% of patients following BGI at 3 years [4] , similar to that reported for the 39% of patients without complications and the 51% of patients with complications who experienced decreased visual acuity in the tube group of TVT at 5 years [25] . In the current study, mean visual acuity was not statistically different at 6 months or 1 year postoperatively from baseline, although a total of four patients did have progression of cataract. Given that results were analyzed at 1 year following BGI in the current study, further follow-up will be required to assess the consistency of these visual acuity outcomes with other reports. Another factor that potentially contributed to unchanged visual acuity was exclusion of failure cases from visual acuity analysis beyond the time point of failure.
This study has several limitations. Like all retrospective studies, no standard protocol was used to collect data at the time of follow-up visits, which may have led to an underestimation of adverse events.
Postoperative interventions and additional medications were left to the discretion of the surgeon, and no standardized protocols were used for postoperative management. The study did not have adequate power to detect rare complications of BGI surgery such as corneal edema or diplopia [4] . Post-operative follow-up was limited to 1 year following surgery, so understanding the long-term effectiveness and complications of BGI requires further inquiry.
This study also had specific inclusion criteria and only examined outcomes in patients who had undergone surgery with the 350 mm 2 Baerveldt glaucoma implant, so it may be difficult to generalize the results to valved tube shunts (e.g. Ahmed valved implant) or other non-valved devices. Finally, the ideal measure of success in any glaucoma therapy is the prevention of further optic nerve damage and visual field loss. While this study focused on lowering IOP as the primary goal of therapy given its well-known role in delaying visual field loss and optic disc progression [26] , further investigation is needed to assess the particular effectiveness of BGI surgery on preventing glaucomatous nerve damage compared to other surgical procedures [9] .
In summary, this study will help provide evidence-based information that will assist in surgical decision making for patients requiring a primary procedure to manage glaucoma.
Primary BGI is effective at reducing IOP at 6 months, significantly decreases the medication burden, and is associated with relatively similar post-operative and visual acuity complications at 1 year compared to results seen in other studies, regardless of prior incisional ocular surgery [4, 25] . The current study adds substantial evidence that primary aqueous shunt implants in general can significantly lower IOP in patients with uncontrolled glaucoma and no prior incisional ocular surgery [27, 28] . While further randomized prospective studies are needed to establish definitively the comparative effectiveness of various procedures in the primary surgical management of patients with uncontrolled glaucoma, the current study supports an ever-expanding role for BGI.
While the risks and benefits of any surgical option must be weighed with respect to the individual characteristics of the patient's disease, this study underscores that BGI is a viable alternative for the primary surgical management of uncontrolled glaucoma. 
CONCLUSIONS

